LifeMine Therapeutics secures $188 million Series E funding from Gates, Bezos and others

LifeMine Therapeutics, a Massachusetts biotech, recently completed a $188 million Series E round, attracting billionaire investors Bill Gates and Jeff Bezos.

The funding follows a $75 million Series D disclosed now, which included existing backers such as GSK and Google Ventures, and helped the company recover after a prior layoff and pause of its fungus‑based platform.

Gates and Bezos were persuaded by LifeMine’s platform that sequences genes from about 100,000 fungal strains and clusters them for drug discovery, prompting them to invest significantly more than the company originally sought.

New investor RA Capital Management also joined the round, bringing the total Series E size to three or four times the company’s initial target.